Results from a randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON).
C. Lhommé, Mario Campone(Institut de Cancérologie de l'Ouest), Dominique Berton-Rigaud(Institut de Cancérologie de l'Ouest), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), A. Stenzl, F. Rolland(Institut de Cancérologie de l'Ouest), Thomas Schmelter, Florence Joly
Cited by 3
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483